TY - JOUR
T1 - Opioid overdose survivors
T2 - Medications for opioid use disorder and risk of repeat overdose in Medicaid patients
AU - Crystal, Stephen
AU - Nowels, Molly
AU - Samples, Hillary
AU - Olfson, Mark
AU - Williams, Arthur Robin
AU - Treitler, Peter
N1 - Funding Information:
This work was supported by the National Institute on Drug Abuse (grants 1R01 DA047347-01, K23 DA044342-01, & K01 DA049950); the Foundation for Opioid Response Efforts; and by NIH’s National Center for Advancing Translational Sciences (grant UL1TR003017). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
We acknowledge the New Jersey Department of Human Services for providing access to data and for their review of this work. Dr. Samples has received consulting fees from the American Society of Addiction Medicine. Dr. Williams receives consulting fees and equity from Ophelia Health, Inc. a telehealth buprenorphine provider. No other authors have conflicts to declare.
Publisher Copyright:
© 2022
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background: Patients with medically-treated opioid overdose are at high risk for subsequent adverse outcomes, including repeat overdose. Understanding factors associated with repeat overdose can aid in optimizing post-overdose interventions. Methods: We conducted a longitudinal, retrospective cohort study using NJ Medicaid data from 2014 to 2019. Medicaid beneficiaries aged 12–64 with an index opioid overdose from 2015 to 2018 were followed for one year for subsequent overdose. Exposures included patient demographics; co-occurring medical, mental health, and substance use disorders; service and medication use in the 180 days preceding the index overdose; and MOUD following index overdose. Results: Of 4898 individuals meeting inclusion criteria, 19.6% had repeat opioid overdoses within one year. Index overdoses involving heroin/synthetic opioids were associated with higher repeat overdose risk than those involving prescription/other opioids only (HR = 1.44, 95% CI = 1.22–1.71). Risk was higher for males and those with baseline opioid use disorder diagnosis or ED visits. Only 21.7% received MOUD at any point in the year following overdose. MOUD was associated with a large decrease in repeat overdose risk among those with index overdose involving heroin/synthetic opioids (HR = 0.30, 95% CI = 0.20–0.46). Among those receiving MOUD at any point in follow-up, 10.5% (112/1065) experienced repeat overdose versus 22.1% (848/3833) for those without MOUD. Conclusions: Repeat overdose was common among individuals with medically-treated opioid overdose. Risk factors for repeat overdose varied by type of opioid involved in index overdose, with differential implications for intervention. MOUD following index opioid overdose involving heroin/synthetic opioids was associated with reduced repeat overdose risk.
AB - Background: Patients with medically-treated opioid overdose are at high risk for subsequent adverse outcomes, including repeat overdose. Understanding factors associated with repeat overdose can aid in optimizing post-overdose interventions. Methods: We conducted a longitudinal, retrospective cohort study using NJ Medicaid data from 2014 to 2019. Medicaid beneficiaries aged 12–64 with an index opioid overdose from 2015 to 2018 were followed for one year for subsequent overdose. Exposures included patient demographics; co-occurring medical, mental health, and substance use disorders; service and medication use in the 180 days preceding the index overdose; and MOUD following index overdose. Results: Of 4898 individuals meeting inclusion criteria, 19.6% had repeat opioid overdoses within one year. Index overdoses involving heroin/synthetic opioids were associated with higher repeat overdose risk than those involving prescription/other opioids only (HR = 1.44, 95% CI = 1.22–1.71). Risk was higher for males and those with baseline opioid use disorder diagnosis or ED visits. Only 21.7% received MOUD at any point in the year following overdose. MOUD was associated with a large decrease in repeat overdose risk among those with index overdose involving heroin/synthetic opioids (HR = 0.30, 95% CI = 0.20–0.46). Among those receiving MOUD at any point in follow-up, 10.5% (112/1065) experienced repeat overdose versus 22.1% (848/3833) for those without MOUD. Conclusions: Repeat overdose was common among individuals with medically-treated opioid overdose. Risk factors for repeat overdose varied by type of opioid involved in index overdose, with differential implications for intervention. MOUD following index opioid overdose involving heroin/synthetic opioids was associated with reduced repeat overdose risk.
KW - Medicaid
KW - Medication for opioid use disorder
KW - Opioid overdose
KW - Opioid use disorder
UR - http://www.scopus.com/inward/record.url?scp=85122655679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122655679&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2022.109269
DO - 10.1016/j.drugalcdep.2022.109269
M3 - Article
C2 - 35038609
AN - SCOPUS:85122655679
SN - 0376-8716
VL - 232
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
M1 - 109269
ER -